Psychedelics Might Be The Most Important Founder Technology Of This Decade

Show Notes

He can stand up a website in forty seconds. That is not the problem.

Funding stage: Seed. Althea raised a $1.5 million seed round from Boulder Ventures and Matchstick Ventures.

Niko Skievaski has been raising venture money since 2013. He co-founded Redox, the healthcare interoperability company that became one of the largest data networks in American health tech, and he watched AI arrive and compress the parts of the job that used to force him to slow down. Research, analysis, first drafts, scaffolding. All of it collapsed toward zero. What he found on the other side of that compression was not free time. It was concentration. “It doesn't actually reduce the psychological load of being a founder. It actually concentrates it.” When you can go from unknowns to three viable options in an afternoon, the entire weight of the job lands on the one thing that did not get faster: your judgment. Your ability to know which bias you brought into the room. Your ability to find signal in noise you generated yourself. Those are not technical skills. AI cannot build them for you.

Niko's answer, and now his company, is Althea, a public benefit corporation building the infrastructure layer for legal, supervised psychedelic therapy in Colorado and Oregon. It started as compliance software for licensed facilitators. It has become a marketplace where a person can find a screened, licensed, reviewed psilocybin experience the way you would book anything else you actually intend to show up for. Althea is formed in partnership with the University of Colorado School of Medicine's Department of Psychiatry, and in January 2026 it acquired Tricycle Day, the psychedelic education newsletter founded by Henry Winslow, now Althea's President.

The origin is not a market thesis. Niko sat with his father a month before he died, with psilocybin, and watched a man who had spent his life arguing about his own addictions stop arguing. “He chose to move into death courageously, in a way that aligned with who he was.” They spent the last days on a beach with beers and Pink Floyd. Niko left Redox in 2022 and went looking for how to point a fifteen-year healthcare technology career at that.

This conversation is not a sales pitch for mushrooms. It is a working founder describing, in specifics, what happens to a person whose identity was built on cognitive output when the cognitive output gets commoditized. It includes the parts that do not fit on a thumbnail: the hero's dose four days before recording that he described as a really challenging experience, the pacing in a hallway, the exhaustion, the gratitude on the other side. It includes who should not do this and why. And it includes a genuinely useful working practice that has nothing to do with psychedelics at all, which is what to do with the ninety seconds while your agent finishes running.

Two-thirds of the people going through Althea's system are not there for mental health. They are there to get unstuck. If you have ever felt like productivity quietly became your entire personality, that number will land.

Named Frameworks

The Execution Compression Problem

Niko's core thesis about why AI made founding harder, not easier.

→AI collapses the time cost of research, analysis, and building. Options arrive faster.
→The steps that used to force you to slow down and think are the exact steps that got automated.
→What remains is judgment, bias awareness, and signal detection, which are non-technical and non-delegable.
→Corollary from the episode: making a founder more productive doesn't make them work less. It makes them work more.

The Two Landings

What happens after ego dissolution, and why the container matters.

→The experience often produces a felt sense of oneness and loss of self-reference. On re-entry, that epiphany resolves in one of two directions.
→Landing one: "I am no different from God, therefore I am powerful, I can do anything." The Messiah complex.
→Landing two: "I am infinitesimally small, and I understand my place in it." Also profound, considerably more workable.
→Founders are structurally predisposed to landing one. Grandiosity is part of the job description. This is exactly why the integration container exists.

The Three-Part Container

Althea's structural answer to set and setting, and the thing that separates this from doing it with your buddies.

→Preparation: weeks before, multiple meetings with the facilitator to clarify what you're actually bringing to the table.
→Administration: the facilitator sits with you, keeping you working the material rather than escaping into music, lights, or scenery.
→Integration: begins immediately on re-entry and continues for months or years. Althea offers ongoing group integration free, indefinitely.
→Regulatory stack underneath all three: licensed facilitator, state-licensed training program, lab-tested medicine, licensed center.

The Neuroplasticity Window

The most actionable idea in the episode, and the one with the widest application.

→Elevated neuroplasticity persists for weeks after a session, largely independent of what happened during it.
→New habits, practices, and mental models install more easily inside that window.
→Ryan's framing: the journey isn't the point. The twenty-eight days afterward are the point.
→Practical use: decide before the session which single habit you're installing, then use the window on that one thing.

The Surrender Gap

Why founders specifically struggle with this work.

→The founder profile: high conviction, grandiose vision, comfort creating ambiguity, strong preference for control.
→Psychedelic work runs the other direction. The requirement is surrender.
→The traits that make you effective at scaling a company are the traits that make this hardest.
→Niko includes himself in this. He is not describing other people.

The Micro-Slip Protocol

Ryan's working practice, and the one thing in this episode you can implement today with zero medicine involved.

→The failure mode: seventy-two tabs, seventeen shells, agents running in parallel, constant toggling, total exhaustion by Friday.
→The alternative: run one agent task. Wait for it. Do not toggle.
→Use the wait as a deliberate rest for attention rather than a gap to fill.
→Reported result: same output, and the day ends with resolve instead of depletion.

Founder Experiment

Run the Single-Thread Sprint, five working days, no substances required, costs nothing. Pick your five heaviest AI-assisted work days this week. Count your open tabs and running shells right now and write the number down, then rate your energy at end of day on a scale of one to ten. For five days, run one agent task at a time. When it's running, you don't open another tab, you don't start a second task, you don't check anything. You wait, hands off the keyboard. Use the wait, sixty to ninety seconds of not directing your attention anywhere, not meditation with a capital M, just stop steering. Every evening, log two numbers: shipped units of real work, and end-of-day energy one to ten. On Friday, compare against Monday's baseline. What you're testing: whether your output was ever actually constrained by parallelism, or whether you've been paying an attention tax and calling it throughput.

Glossary

Psilocybin

The psychoactive compound in certain mushrooms. In Colorado's regulated program, dosing is measured in milligrams of active psilocybin, not grams of mushroom.

Macrodose

A full, perceptually altering dose taken infrequently. Niko's pattern is one every six to twelve months over roughly twelve years.

Hero's dose

Informal term for a high-end macrodose. Niko's most recent was 25 mg of psilocybin.

Default mode network

The brain network associated with self-referential narrative, the inner monologue, and judgment. fMRI work shows psychedelics temporarily quiet it.

Ego dissolution

The temporary loss of the sense of a separate self, commonly reported when the default mode network goes quiet.

Set and setting

Mindset and physical or social environment. The two variables most predictive of how a psychedelic experience goes.

Integration

The structured work of translating insights into behavior after a session. Not optional. Althea provides it free and ongoing.

Facilitator

In Colorado, a state-licensed role created specifically for supervising psychedelic sessions.

Natural Medicine Health Act, Proposition 122

Colorado's 2022 ballot measure. Decriminalized personal use and sharing of certain natural psychedelics, and created the regulated supervised-use framework.

EO 14401

The April 18, 2026 executive order directing FDA to prioritize psychedelic review, instructing DEA and other agencies to reduce research restrictions, and allocating $50 million.

Q&A: What Founders Ask After This Episode

Is psilocybin therapy legal in the United States?

Not federally. Psilocybin remains Schedule I. Two states, Colorado and Oregon, run legal supervised-use programs where adults 21 and over can access psilocybin through licensed facilitators in licensed centers without a diagnosis. New Mexico's medical psilocybin program is in development, requiring a qualifying medical condition.

Do you need a mental health diagnosis to access psilocybin in Colorado or Oregon?

No. Both programs are open to adults 21 and over who pass health screening. This is the key structural difference from a clinical trial or from New Mexico's medical model.

Why are startup founders using psychedelics?

Per Althea's own data, roughly two-thirds of participants are not primarily there for mental health. The stated reasons are creativity, spirituality, exploring consciousness, and getting unstuck. Niko Skievaski's specific framing for founders is finding clarity, conviction, and the courage to do work that scares them.

How much does legal psilocybin therapy cost?

Niko cites roughly $2,500 for an average journey. Full programs including preparation and integration run higher. It's out of pocket since insurance doesn't cover it, because the substance is federally illegal. Althea runs the Forward Fund with nonprofit partner Thank You Life to provide scholarships.

What did Trump's psychedelics executive order actually do?

EO 14401, signed April 18, 2026, directs the FDA to prioritize review of psychedelic compounds, instructs the DEA and other agencies to reduce research restrictions, allocates $50 million for federal and state collaboration, and creates a Right to Try pathway for eligible patients to access investigational psychedelics including ibogaine. It did not reschedule anything.

Does AI make founding easier?

Niko Skievaski argues it does not. AI compresses execution, which means the psychological load of the job concentrates onto judgment, bias awareness, and decision-making, none of which AI improves. Founders get to more options faster and then have to choose, with less thinking time built into the process.

What is the neuroplasticity window after psilocybin?

An extended period, described on this episode as weeks and roughly twenty-eight days, of elevated capacity to form new habits and update mental models, which persists regardless of what happened during the session itself.

What is Althea?

A Boulder, Colorado public benefit corporation building software and a marketplace for legal, regulated psychedelic therapy in Colorado and Oregon. Founded by Niko Skievaski, formed in partnership with the University of Colorado School of Medicine's Department of Psychiatry. It raised a $1.5 million seed round from Boulder Ventures and Matchstick Ventures and acquired the Tricycle Day newsletter in January 2026.

Who is Niko Skievaski?

Co-founder and CEO of Althea. Previously co-founder and President of Redox, the healthcare interoperability platform he started in 2014 with Luke Bonney and James Lloyd after all three left Epic. Redox raised $95 million. He lives in Boulder, Colorado, writes a psychedelics column for Boulder Weekly, and served on Denver's Natural Medicine Work Group.

URLs Mentioned in the Episode

Altheahttps://withalthea.com
Browse legal experienceshttps://be.withalthea.com/experiences
The Forward Fundhttps://withalthea.com/forward-fund/
Tricycle Day newsletterhttps://www.tricycleday.com/
Niko Skievaski on LinkedInhttps://www.linkedin.com/in/skievaski/
Ryan Estes on LinkedInhttps://www.linkedin.com/in/estesryan/
AI for Foundershttps://aiforfounders.co
Inbox Alchemyhttps://inboxalchemy.co